Astellas Pharma (ALPMY) News Today $9.68 -0.21 (-2.12%) As of 01/31/2025 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest UpdateAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a significant decrease in short interest in January. As of January 15th, there was short interest totalling 31,500 shares, a decrease of 58.7% from the December 31st total of 76,200 shares. Based on an average trading volume of 787,700 shares, the short-interest ratio is currently 0.0 days.January 29 at 3:39 AM | marketbeat.comJefferies Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)January 25, 2025 | markets.businessinsider.comAstellas Pharma (OTCMKTS:ALPMY) Hits New 12-Month Low - Here's What HappenedAstellas Pharma (OTCMKTS:ALPMY) Reaches New 52-Week Low - What's Next?January 24, 2025 | marketbeat.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Declines By 58.7%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 31,500 shares, a decrease of 58.7% from the December 15th total of 76,200 shares. Based on an average daily volume of 787,700 shares, the days-to-cover ratio is presently 0.0 days.January 14, 2025 | marketbeat.comFDA Accepts Astellas Pharma's Revised SNDA For IZERVAY In Geographic Atrophy TreatmentJanuary 9, 2025 | markets.businessinsider.comAstellas Pharma : China's NMPA Approves VYLOY For Advanced Gastric/Gastroesophageal Junction CancerJanuary 5, 2025 | markets.businessinsider.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Increases By 150.7%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 76,200 shares, an increase of 150.7% from the November 30th total of 30,400 shares. Based on an average daily volume of 559,900 shares, the days-to-cover ratio is currently 0.1 days.December 27, 2024 | marketbeat.comAxcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein DegradersDecember 25, 2024 | businesswire.comAstellas and Sangamo sign capsid deal for neurological diseasesDecember 20, 2024 | msn.comAstellas Pharma (OTCMKTS:ALPMY) Share Price Passes Below 200-Day Moving Average - What's Next?Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?December 19, 2024 | marketbeat.comAstellas In Deal With Sangamo For STAC-BBB Capsid To Deliver Genomic MedicinesDecember 19, 2024 | markets.businessinsider.comAstellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for ThemselvesDecember 5, 2024 | prnewswire.comAstellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure ManagementNovember 20, 2024 | prnewswire.comAstellas Faces FDA Setback on IZERVAY ApplicationNovember 18, 2024 | markets.businessinsider.comAstellas Pharma H1 Profit Rises; Lifts FY24 OutlookOctober 30, 2024 | markets.businessinsider.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Growth in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totalling 45,100 shares, an increase of 16.2% from the September 30th total of 38,800 shares. Based on an average trading volume of 182,400 shares, the days-to-cover ratio is presently 0.2 days.October 29, 2024 | marketbeat.comAstellas Pharma Withdraws EU Application for Key DrugOctober 28, 2024 | markets.businessinsider.comBernstein Releases a Buy Rating on Astellas Pharma (ALPMF)October 23, 2024 | markets.businessinsider.comAstellas Pharma’s VYLOY Gains FDA Approval for Cancer TreatmentOctober 21, 2024 | markets.businessinsider.comAstellas Pharma's Cancer Drug Vyloy Gets FDA ApprovalOctober 19, 2024 | marketwatch.comAstellas Pharma's VYLOY Receives FDA Approval For Treatment Of Advanced Gastric And GEJ CancerOctober 19, 2024 | markets.businessinsider.comAstellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ CancerOctober 18, 2024 | prnewswire.comFDA approves Astellas' gastric cancer therapyOctober 18, 2024 | reuters.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Growth in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 38,800 shares, an increase of 269.5% from the September 15th total of 10,500 shares. Based on an average trading volume of 139,900 shares, the short-interest ratio is currently 0.3 days.October 10, 2024 | marketbeat.comAstellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on MenopauseOctober 10, 2024 | prnewswire.comAstellas Receives Option To License AVB-101 - Quick FactsOctober 9, 2024 | markets.businessinsider.comAstellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other IndicationsOctober 8, 2024 | prnewswire.comSinglera Genomics and Astellas Present Methylation-based Organ Toxicity Detection at 2024 JSOT Annual MeetingOctober 1, 2024 | businesswire.comPoseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B AdvancementSeptember 30, 2024 | seekingalpha.comHere are the Medicare Part D drugs expected to face 2025 price negotiationsSeptember 29, 2024 | seekingalpha.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Decrease in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 10,500 shares, a drop of 75.4% from the August 31st total of 42,600 shares. Based on an average daily volume of 201,200 shares, the days-to-cover ratio is presently 0.1 days.September 25, 2024 | marketbeat.comAstellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction CancerSeptember 20, 2024 | prnewswire.comAstellas Announces FDA Listing Of DIGITIVA For Heart Failure ManagementSeptember 18, 2024 | markets.businessinsider.comAstellas Announces FDA Listing of DIGITIVA™ for the Management of Heart FailureSeptember 18, 2024 | prnewswire.comAstellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024September 11, 2024 | prnewswire.comAstellas opens lab, offices in Cambridge CrossingSeptember 6, 2024 | bizjournals.comAstellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough TherapiesSeptember 5, 2024 | prnewswire.comAstellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause SocietySeptember 4, 2024 | prnewswire.comSanten Pharmaceutical Co., Ltd. (SZD.F)August 30, 2024 | sg.finance.yahoo.comAstellas : EC Approves PADCEV Combination For First-Line Treatment Of Advanced Urothelial CancerAugust 27, 2024 | markets.businessinsider.comEuropean Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial CancerAugust 27, 2024 | prnewswire.comAstellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine TherapyAugust 27, 2024 | prnewswire.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 11.9% in JulyAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a large decrease in short interest in July. As of July 31st, there was short interest totalling 298,700 shares, a decrease of 11.9% from the July 15th total of 338,900 shares. Based on an average daily trading volume, of 530,700 shares, the days-to-cover ratio is currently 0.6 days.August 17, 2024 | marketbeat.comAstellas' zolbetuximab gains UK approval for gastric cancerAugust 16, 2024 | msn.comUK regulator approves Astellas' gastric cancer drugAugust 14, 2024 | reuters.comAstellas Pharma (OTCMKTS:ALPMY) Share Price Crosses Above 50 Day Moving Average of $10.38Astellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Above 50-Day Moving Average of $10.38August 14, 2024 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Share Price Crosses Above 50-Day Moving Average of $10.18Astellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Above 50 Day Moving Average of $10.18August 6, 2024 | marketbeat.comSmall-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor DataAugust 5, 2024 | finance.yahoo.comAstellas: Zolbetuximab Combo Gets Positive CHMP Opinion In Advanced Gastric &Gastroesophageal CancerJuly 28, 2024 | markets.businessinsider.comAstellas Wins CHMP Backing for Treatments Aimed at Bladder, Gastric CancerJuly 27, 2024 | marketwatch.com Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address ALPMY Media Mentions By Week ALPMY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALPMY News Sentiment▼0.640.69▲Average Medical News Sentiment ALPMY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALPMY Articles This Week▼31▲ALPMY Articles Average Week Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TAK News Today UCBJF News Today ALNY News Today TEVA News Today BAYRY News Today MKKGY News Today MKGAF News Today RPRX News Today BGNE News Today SMMT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ALPMY) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
